Oncolytics Biotech Inc. (ONC.TO)
Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
At close: 04:00PM EST
| Previous Close | 2.4800 |
| Open | 2.4600 |
| Bid | 2.4200 x 0 |
| Ask | 2.4400 x 0 |
| Day's Range | 2.4200 - 2.4900 |
| 52 Week Range | 1.0600 - 3.1000 |
| Volume | |
| Avg. Volume | 78,730 |
| Market Cap | 146.391M |
| Beta (5Y Monthly) | 1.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4820 |
| Earnings Date | Mar 01, 2023 - Mar 06, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.25 |
- Zacks
Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year?
Here is how DICE Therapeutics, Inc. (DICE) and Oncolytics Biotech Inc. (ONCY) have performed compared to their sector so far this year.
- Baystreet
Stocks in play: Oncolytics Biotech Inc
Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging ...
- CNW Group
Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
Oncolytics Biotech® Inc.'s (NASDAQ: ONCY) (TSX: ONC) Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging clinical trial to evaluate the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced/metastatic HR+/HER2- breast cancer. The data were featured in a poster presented yesterday at the San Antonio Breast Cancer Symposium (SABCS), which is being held at the Henry B. González C
© 2023 Yahoo. All rights reserved.
